.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The PROPPR randomized clinical trial compared two transfusion strategies for patients with severe trauma and major haemorrhage: a 1:1:1 ratio of plasma, platelets and red blood cells versus a 1:1:2 ratio. The study addressed the practical challenge of how best to balance blood components during early resuscitation. The trial did not demonstrate a significant difference in overall mortality between the two groups, but the 1:1:1 strategy achieved better haemostatic outcomes, including more effective control of exsanguination and improved achievement of haemostasis in the early period. For surgeons, PROPPR is a reminder that trauma resuscitation is about more than simply replacing circulating volume. Balanced blood-component resuscitation can influence the ability to control bleeding while definitive haemorrhage control is pursued. The study also demonstrates why transfusion protocols need to be standardized before the emergency occurs. Rapid access to blood components, coordination with the operating theatre and trauma team, and clear activation pathways are critical to translating trial evidence into practice. PROPPR therefore remains highly relevant to trauma systems, particularly when designing massive transfusion protocols and training teams to respond consistently under pressure.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The PROPPR randomized clinical trial compared two transfusion strategies for patients with severe trauma and major haemorrhage: a 1:1:1 ratio of plasma, platelets and red blood cells versus a 1:1:2 ratio. The study addressed the practical challenge of how best to balance blood components during early resuscitation. The trial did not demonstrate a significant difference in overall mortality between the two groups, but the 1:1:1 strategy achieved better haemostatic outcomes, including more effective control of exsanguination and improved achievement of haemostasis in the early period. For surgeons, PROPPR is a reminder that trauma resuscitation is about more than simply replacing circulating volume. Balanced blood-component resuscitation can influence the ability to control bleeding while definitive haemorrhage control is pursued. The study also demonstrates why transfusion protocols need to be standardized before the emergency occurs. Rapid access to blood components, coordination with the operating theatre and trauma team, and clear activation pathways are critical to translating trial evidence into practice. PROPPR therefore remains highly relevant to trauma systems, particularly when designing massive transfusion protocols and training teams to respond consistently under pressure.
Yesterday
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
